COMMUNIQUÉS West-GlobeNewswire

Market launch of the nasal adrenaline spray, neffy®, for treatment of adults and children with severe allergies in Canada
05/08/2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced the market launch of neffy ® 2 mg in Canada following the approval by Health Canada in April 2026. The launch of this first ever nasal adrenaline spray for [...]
Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update
05/08/2026
-- Reaffirms 2026 Guidance -- -- Multiple New Business Wins, Adding Impactful Programs to Pipeline -- -- Cost Reduction and Productivity Enhancements Continue to Strengthen Organization -- Conference Call Today at 8: [...]
Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026
05/08/2026
RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release [...]
AC Immune First Half 2026 Financial and Corporate Update
05/08/2026
AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances across pipeline, [...]
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
05/08/2026
BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral [...]
Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences
05/08/2026
BERKELEY HEIGHTS, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biotechnology company, today announced that [...]
Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026
05/08/2026
Company to Host Conference Call at 8:30am ET REHOVOT, Israel, and HOBOKEN, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of [...]
Verano Announces Strong Second Quarter 2026 Financial Results Highlighted by $218 Million in Revenue
05/08/2026
Company delivers third consecutive quarter of revenue gains and improved cash flow from operations driven by organic growth CHICAGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO [...]
Shopify Delivers Big: 30%+ Growth Across GMV, Revenue, Gross Profit, and Free Cash Flow
05/08/2026
Internet, Everywhere, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Shopify (NASDAQ, TSX: SHOP) announced today financial results for the quarter ended June 30, 2026. Shopify achieved 34% revenue growth (33% in constant currency) [...]
Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy
05/08/2026
RMAT designation granted based on recent interim clinical data from ongoing Phase I/II clinical trial evaluating LX2020 for PKP2-ACM LX2020 now holds RMAT, Orphan Drug and Fast Track designations by the FDA NEW YORK, [...]
Telix to Host R&D Day in New York City on September 22, 2026
05/08/2026
MELBOURNE, Australia and INDIANAPOLIS, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will host a Research and Development (R&D) Day on Tuesday [...]
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
05/08/2026
Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026 KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 [...]
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
05/08/2026
– Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe – – PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 – – Topline data from [...]
BioCryst Reports Second Quarter 2026 Financial Results
05/08/2026
— Total net revenue of $218.3 million and ORLADEYO ® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 million — — Maintained Full Year 2026 ORLADEYO revenue [...]
Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights
05/08/2026
Achieved $57.5 million in RYTELO ® (imetelstat) net product revenue in Q2 2026, an increase of 11% compared to Q1 2026 Reiterated 2026 RYTELO net product revenue and total operating expenses expected to be in the ranges [...]
Marvel Biosciences Reports Positive Preclinical Data Demonstrating MB-204 Reverses Behavioural and Cognitive Deficits in a Mouse Model of Fragile X
05/08/2026
CALGARY, Alberta, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF ), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug [...]
Bluesight Launches Revenue Optimization Capabilities, Expanding Margin Insights for Hospital Pharmacies
05/08/2026
Alexandria, Virginia, Aug. 05, 2026 (GLOBE NEWSWIRE) -- CostCheck, a drug procurement optimization tool used by more than 500 hospitals, now factors in top-line revenue alongside cost savings to provide pharmacy teams a [...]
Mironid raises $46 million in Series B financing to advance clinical development of its treatment for rare kidney disease
05/08/2026
Scottish National Investment Bank joins existing investors Roche Venture Fund, Epidarex Capital, Sofinnova Partners and BioGeneration Ventures Glasgow, Scotland, August 5, 2026 – Mironid, a biopharmaceutical company [...]
Basilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
05/08/2026
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 05, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of [...]

Pages